AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders

 AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders

AbCellera and Denali Therapeutics Expand Collaboration to Develop Abs for Neurological Disorders

Shots: 

  • AbCellera to receive technology access fee, milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders
  • On 12 Jun,2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases 
  • AbCellera’s single-cell screening technology is a combination of live-cell assays to develop therapies for targets such as membrane proteins, GPCRs and ion channels in multiple therapy areas

Click here to read full press release/ article | Ref: AbCellera | Image: Evaluating Pharmacy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post